We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Sartorius Stedim Biotech and GE Healthcare Life Sciences Sign Agreement for Biopharmaceutical Manufacturing Technologies

By LabMedica International staff writers
Posted on 21 Sep 2011
Sartorius Stedim Biotech (Aubagne, France) has entered into a patent cross-licensing agreement with GE Healthcare Life Sciences (Chalfont St. More...
Giles, UK). This will enable the further development of each company’s current and future biopharmaceutical manufacturing technologies.

“Signing this agreement represents our mutual respect for intellectual property. In the immediate term it will enable us to employ the technologies covered by the patents in the license agreements to further advance the controls of single use devices,” said Catarina Flyborg, general manager, bioprocess products at GE Healthcare Life Sciences. “Furthermore, our customers will profit from the freedom to employ these proprietary control mechanisms, without violating patent rights, when sourced from either GE Healthcare Life Sciences or Sartorius Stedim Biotech.”

Reinhard Vogt, executive vice president of marketing, sales and services, Sartorius Stedim Biotech, commented, “Like GE Healthcare Life Sciences, we have primarily entered into these license agreements for the benefit of our customers. The agreement will enable both our companies to provide a greater selection of products as well as accelerate the development of new and innovative technologies for applications in the biopharmaceutical manufacturing industry.”

Under the agreement, Sartorius Stedim Biotech has granted GE Healthcare Life Sciences a sublicense to certain patents held by the University of Maryland (UMBC; College Park, USA) to which Sartorius Stedim Biotech has access under an exclusive license agreement with Fluorometrix, a spin-off of UMBC. These patent rights cover bioreactors with at least two optical sensors for monitoring biotechnologic manufacturing processes. GE Healthcare Life Sciences has granted Sartorius Stedim Biotech a sublicense to patent rights that it has licensed from SciLog, Inc. (Middleton, WI, USA), a leading innovator in automated and single-use purification systems as well as disposable sensor technology. These patent rights cover proprietary technologies for the automated, aseptic transfer of solutions in bioprocessing applications. The financial terms of the agreement were not disclosed.

Sartorius Stedim Biotech is a provider of cutting-edge equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management, and lab technologies are supporting the biopharmaceutical industry worldwide to develop and produce drugs safely, timely, and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves.

GE Healthcare’s expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help their customers across the healthcare spectrum deliver better services at lower cost.

Related Links:
Sartorius Stedim Biotech
GE Healthcare Life Sciences
University of Maryland



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
New
Portable POCT Blood Gas Analyzer
BD100
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers identified 157 metabolites linked to BBB damage, including 25 that appeared in at least two independent studies (Image Credit: Adobe Stock)

Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury

Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.